Treatments

Long-Term Efficacy, Safety of Metreleptin for Generalized Lipodystrophy

Long-Term Efficacy, Safety of Metreleptin for Generalized Lipodystrophy

By

Investigators examined the safety and efficacy of metreleptin in patients with congenital or acquired generalized lipodystrophy.

Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D

Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D

By

Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.

Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes

Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes

By

Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.

Glyburide is not noninferior to insulin in reducing perinatal complications in gestational diabetes

In this randomized controlled trial, glyburide was not noninferior in terms of the composite rate of macrosomia, neonatal hypoglycemia, and hyperbilirubinemia compared with subcutaneous insulin.

SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study

SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study

By

Study compared the real-world effectiveness of canagliflozin 300 mg vs dapagliflozin 10 mg on HbA1c reduction in patients with type 2 diabetes.

Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy

Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy

By

Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.

SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for type 2 diabetes

SGLT-2 inhibitors or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

By

Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.

More Adverse Events and Higher Costs for Patients With RA on High-Dose Glucocorticoids

More Adverse Events and Higher Costs for Patients With RA on High-Dose Glucocorticoids

Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.

DPP-4 Inhibitors Not Tied to Increased Risk for Acute Pancreatitis in Seniors

DPP-4 Inhibitors Not Tied to Increased Risk for Acute Pancreatitis in Seniors

Study provides evidence that DPP-4 inhibitors are not associated with an increased risk of acute pancreatitis in older adults overall. The positive association observed in patients with CVD could be due to chance or bias but merits further investigation.

Consensus Report Defines Treatment Success in β-Cell Replacement Therapy

Consensus Report Defines Treatment Success in β-Cell Replacement Therapy

By

IPITA and EPITA held a workshop to develop consensus for a joint statement on the definition of function and failure of current and future forms of β-cell replacement therapy.

Safety, Efficacy of Degludec/Liraglutide Fixed-Ratio Combination in Uncontrolled T2D

Safety, Efficacy of Degludec/Liraglutide Fixed-Ratio Combination in Uncontrolled T2D

By

IDegLira provides an efficacious intensification option with noninferior glycemic control vs basal-bolus in patients with type 2 diabetes receiving 20 to 50 units of basal insulin with no renal impairment and HbA1c levels of 7% to 10%.

Add-On Antihypertensives Compared in Patients With Diabetes on ACEIs, ARBs

Add-On Antihypertensives Compared in Patients With Diabetes on ACEIs, ARBs

By

The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.

Bydureon Single Dose Trays to Be Discontinued

Bydureon Single Dose Trays to Be Discontinued

By

The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays.

Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D

Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D

By

The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.

Bremelanotide NDA Submitted to FDA for Hypoactive Sexual Desire Disorder

Bremelanotide NDA Submitted to FDA for Hypoactive Sexual Desire Disorder

By

Bremelanotide, an investigational product, is thought to possess a novel mechanism of action, activating endogenous melanocortin pathways involved in sexual desire and response.

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

By

In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.

Treating Moderate to Severe Graves' Orbitopathy: Methylprednisolone Alone vs Combined With Mycophenolate

Treating Moderate to Severe Graves' Orbitopathy: Methylprednisolone Alone vs Combined With Mycophenolate

By

This study is the first to investigate the efficacy and safety of add-on mycophenolate to methylprednisolone for moderate to severe Graves' orbitopathy.

Prior Authorization Requirements Greater for PCSK9 Inhibitors

Prior Authorization Requirements Greater for PCSK9 Inhibitors

Prior authorization requirements are greater for proprotein convertase subtilisin/kexin type 9 inhibitors than for other cardiometabolic drugs.

Metformin After Insulin Therapy Induction Beneficial in Long-Term

Metformin After Insulin Therapy Induction Beneficial in Long-Term

After induction short-term intensive insulin therapy, metformin is superior to intermittent IIT for maintaining beta-cell function and glycemic control over 2 years.

Risk for Congenital Malformations With Antithyroid Drugs

Risk for Congenital Malformations With Antithyroid Drugs

By

Antithyroid drug exposure during the first trimester was associated with an increased risk for congenital malformations.

Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease

Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease

By

This is the first study to have validated a metformin dose adjustment as a function of the estimated glomerular filtration rate in patients with type 2 diabetes and chronic kidney disease.

NovoFine 30G 8mm Pen Needle Will Be Discontinued

NovoFine 30G 8mm Pen Needle Will Be Discontinued

By

Novo Nordisk has announced that the NovoFine 30G 8mm pen needle will be discontinued on or before April 30, 2018.

First trimester exposure to antithyroid drugs associated with increased risk of birth defects

First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.

Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D

Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D

By

Patients identified with increased insulin resistance following intra-articular corticosteroid injection or any systemic steroid treatment might need a special emphasis regarding management and followup.

Preoperative Liraglutide May Stabilize Postoperative Plasma Glucose in T2D

Preoperative Liraglutide May Stabilize Postoperative Plasma Glucose in T2D

For patients with type 2 diabetes undergoing non-cardiac surgery, premedication with liraglutide is associated with reduced median plasma glucose 1 hour postoperatively.

FDA Accepts New Drug Application for Treatment of Rare Neuroendocrine Tumors

FDA Accepts New Drug Application for Treatment of Rare Neuroendocrine Tumors

By

The Food and Drug Administration has accepted the New Drug Application for Azedra for the treatment of malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma.

FDA Approves 3 New Drugs for T2D in Adults

FDA Approves 3 New Drugs for T2D in Adults

By

Steglatro is indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and Steglujan is indicated as adjunct when treatment with both ertugliflozin and sitagliptin are appropriate.

Levothyroxine in Pregnancy Did Not Affect Neonatal Admission Rates

Levothyroxine in Pregnancy Did Not Affect Neonatal Admission Rates

By

Study aimed to evaluate the benefits of levothytoxine treatment on pregnancy outcomes in subclinical hypothyroid pregnant women who are negative for thyroid peroxidase antibody.

Optimal Dose of Linagliptin Determined for Pediatric T2D

Optimal Dose of Linagliptin Determined for Pediatric T2D

By

Study sought to determine the optimal dosing of linagliptin for the treatment of children with type 2 diabetes.

Sign Up for Free e-Newsletters



CME Focus